Search
Atopic Dermatitis Paid Clinical Trials in Colorado
A listing of 7 Atopic Dermatitis clinical trials in Colorado actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 7 of 7
The state of Colorado currently has 7 active clinical trials seeking participants for Atopic Dermatitis research studies. These trials are conducted in various cities, including Denver, Aurora, Colorado Springs and Englewood.
Featured Trial
Atopic Dermatitis (Eczema) Study (Ages 12 to 17)
Recruiting
Featured Trial
Atopic Dermatitis (Eczema) Study
Recruiting
Featured Trial
Eczema (Atopic dermatitis) Trials
Recruiting
Eczema (Atopic dermatitis) trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
Eczema (Atopic dermatitis)
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Research Study
Recruiting
Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Sinusitis
Featured Trial
Healthy Volunteer Trials
Recruiting
Healthy trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
Healthy
A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD)
Recruiting
The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy and combination therapy treatment in adolescent subjects.
Gender:
All
Ages:
Between 12 years and 17 years
Trial Updated:
06/19/2024
Locations: Velocity Clinical Research - Denver, Denver, Colorado
Conditions: Atopic Dermatitis
A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
Recruiting
The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.
Gender:
All
Ages:
Between 12 years and 100 years
Trial Updated:
06/19/2024
Locations: IMMUNOe Research Centers, Centennial, Colorado
Conditions: Atopic Dermatitis
A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
Recruiting
The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic dermatitis (AD). AD is a long- lasting itchy red rash, caused by a skin reaction.
This study is seeking participants who:
are 18 years of age or more.
Were confirmed to have AD at least 6 months ago.
Are not having an effective treatment result from medicines that are applied on skin for AD.
Are considered by their doctors to have moderate to severe... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/16/2024
Locations: AboutSkin Research, LLC, Greenwood Village, Colorado
Conditions: Atopic Dermatitis
Seal, Stopping Eczema and Allergy Study
Recruiting
This is a randomized, controlled trial designed for children who are have already developed atopic dermatitis (AD or eczema) by 12 weeks of age. The aim is to compare the effect of proactive sequential skin care, including the twice-daily use of a tri-lipid skin barrier cream (Epiceram) and proactive use of fluticasone propionate cream, against reactive AD therapy, to reduce the occurrence and severity of AD in early infancy and thereby prevent food allergy (FA).
Gender:
All
Ages:
Between 1 week and 12 weeks
Trial Updated:
05/08/2024
Locations: Division of Pediatric Allergy and Clinical Immunology, National Jewish Health, Denver, Colorado
Systems Biology of Early Atopy
Recruiting
The goal of this study is to establish a birth cohort that collects prenatal and early life biosamples and environmental samples and rigorously phenotypes young children for food allergy and Atopic Dermatitis (AD) to identify prenatal and early life markers of high risk for food allergy and AD, as well as biological pathways (endotypes) that result in these conditions.
Primary Objectives:
To study the role and interrelationships of established and novel clinical, environmental, biological, and... Read More
Gender:
All
Ages:
0 years and above
Trial Updated:
04/23/2024
Locations: National Jewish Health, Denver, Colorado
Conditions: Allergic Diseases, Food Allergy, Atopic Dermatitis
Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis
Recruiting
This is a multi-center, longitudinal study which will characterize the gene expression profiles and transcriptomic endotypes that underlie mild and moderate-severe Atopic dermatitis (AD) and will determine changes in these expression patterns and endotypes in response to standard-of-care treatment. Participants will complete up to ten scheduled study visits with assessment of topical steroid response and dupilumab response (if uncontrolled with topical steroids). Skin samples will be collected a... Read More
Gender:
All
Ages:
6 years and above
Trial Updated:
01/31/2024
Locations: National Jewish Health: Division of Pediatric Allergy and Clinical Immunology, Denver, Colorado
Conditions: Atopic Dermatitis
Tofacitinib for Immune Skin Conditions in Down Syndrome
Recruiting
People with Down syndrome (DS) display widespread immune dysregulation, including several immune skin conditions. This study hypothesizes that pharmacological inhibition of the increased interferon (IFN) signaling seen in DS is safe and could improve associated skin conditions.
The study evaluates the safety and efficacy treatment with Tofacitinib, an FDA-approved drug known to block IFN signaling, in adolescents and adults with DS and an autoimmune and/or autoinflammatory skin condition. Inves... Read More
Gender:
All
Ages:
Between 12 years and 50 years
Trial Updated:
01/19/2024
Locations: Linda Crnic Institute for Down Syndrome, Aurora, Colorado
Conditions: Down Syndrome, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Alopecia Areata, Atopic Dermatitis / Eczema
1 - 7 of 7